Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Standard
Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. / Ortí, Guillermo; Gras, Luuk; Zinger, Nienke; Finazzi, Maria Chiara; Sockel, Katja; Robin, Marie; Forcade, Edouard; Avenoso, Daniele; Kröger, Nicolaus; Finke, Jürgen; Radujkovic, Aleksandar; Hunault-Berger, Mathilde; Schroyens, Wilfried; Zuckerman, Tsila; Bourhis, Jean Henri; Chalandon, Yves; Bloor, Adrian; Schots, Rik; de Wreede, Liesbeth C; Drozd-Sokolowska, Joana; Raj, Kavita; Polverelli, Nicola; Czerw, Tomasz; Hernández-Boluda, Juan Carlos; McLornan, Donal; Yakoub-Agha, Ibrahim.
in: AM J HEMATOL, Jahrgang 98, Nr. 4, 04.2023, S. 628-638.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
AU - Ortí, Guillermo
AU - Gras, Luuk
AU - Zinger, Nienke
AU - Finazzi, Maria Chiara
AU - Sockel, Katja
AU - Robin, Marie
AU - Forcade, Edouard
AU - Avenoso, Daniele
AU - Kröger, Nicolaus
AU - Finke, Jürgen
AU - Radujkovic, Aleksandar
AU - Hunault-Berger, Mathilde
AU - Schroyens, Wilfried
AU - Zuckerman, Tsila
AU - Bourhis, Jean Henri
AU - Chalandon, Yves
AU - Bloor, Adrian
AU - Schots, Rik
AU - de Wreede, Liesbeth C
AU - Drozd-Sokolowska, Joana
AU - Raj, Kavita
AU - Polverelli, Nicola
AU - Czerw, Tomasz
AU - Hernández-Boluda, Juan Carlos
AU - McLornan, Donal
AU - Yakoub-Agha, Ibrahim
N1 - © 2023 Wiley Periodicals LLC.
PY - 2023/4
Y1 - 2023/4
N2 - Allogeneic hematopoietic cell transplant (allo-HCT) provides the only potential route to long-term remission in patients diagnosed with blast phase transformation of myeloproliferative neoplasm (BP-MPN). We report on a large, retrospective European Society for Blood and Marrow Transplantation registry-based study of BP-MPN patients undergoing allo-HCT. BP-MPN patients undergoing first allo-HCT between 2005 and 2019 were included. A total of 663 patients were included. With a median follow-up of 62 months, the estimated 3-year overall survival (OS) was 36% (95% confidence interval [CI], 32-36). Factors associated with lower OS were Karnofsky Performance Score (KPS) <90 (hazard ratio [HR] 1.65, p < .001) and active disease at allo-HCT (HR 1.45, p < .001), whereas patients undergoing allo-HCT more recently associated with a higher OS (HR 0.96, p = .008). In a selected patient's population, the 3-year OS of patients undergoing allo-HCT in complete response (CR) and with a KPS ≥90 was 60%. KPS < 90 (HR 1.4, p = .001) and active disease (HR 1.44, p = .0004) were associated with a lower progression-free survival (PFS). Conversely, most recent allo-HCT associated with a higher PFS (HR 0.96, p = .008). Active disease at allo-HCT (HR 1.34, p = .03) was associated with a higher cumulative incidence of relapse (RI) and allo-HCT in earlier calendar years (HR 0.96, p = .02) associated with a lower RI. Last, KPS < 90 (HR 1.91, p < .001), active disease (HR 1.74, p = .003) and allo-HCT from mismatched related donors were associated with a higher non-relapse mortality (HR 2.66, p = .003). In this large series of BP-MPN patients, about one third were alive at 3 years after transplantation. Patients undergoing allo-HCT in the more recent era, with a KPS ≥90 and in CR at transplant had a better prognosis.
AB - Allogeneic hematopoietic cell transplant (allo-HCT) provides the only potential route to long-term remission in patients diagnosed with blast phase transformation of myeloproliferative neoplasm (BP-MPN). We report on a large, retrospective European Society for Blood and Marrow Transplantation registry-based study of BP-MPN patients undergoing allo-HCT. BP-MPN patients undergoing first allo-HCT between 2005 and 2019 were included. A total of 663 patients were included. With a median follow-up of 62 months, the estimated 3-year overall survival (OS) was 36% (95% confidence interval [CI], 32-36). Factors associated with lower OS were Karnofsky Performance Score (KPS) <90 (hazard ratio [HR] 1.65, p < .001) and active disease at allo-HCT (HR 1.45, p < .001), whereas patients undergoing allo-HCT more recently associated with a higher OS (HR 0.96, p = .008). In a selected patient's population, the 3-year OS of patients undergoing allo-HCT in complete response (CR) and with a KPS ≥90 was 60%. KPS < 90 (HR 1.4, p = .001) and active disease (HR 1.44, p = .0004) were associated with a lower progression-free survival (PFS). Conversely, most recent allo-HCT associated with a higher PFS (HR 0.96, p = .008). Active disease at allo-HCT (HR 1.34, p = .03) was associated with a higher cumulative incidence of relapse (RI) and allo-HCT in earlier calendar years (HR 0.96, p = .02) associated with a lower RI. Last, KPS < 90 (HR 1.91, p < .001), active disease (HR 1.74, p = .003) and allo-HCT from mismatched related donors were associated with a higher non-relapse mortality (HR 2.66, p = .003). In this large series of BP-MPN patients, about one third were alive at 3 years after transplantation. Patients undergoing allo-HCT in the more recent era, with a KPS ≥90 and in CR at transplant had a better prognosis.
KW - Humans
KW - Retrospective Studies
KW - Hematopoietic Stem Cell Transplantation/adverse effects
KW - Transplantation, Homologous/adverse effects
KW - Blast Crisis/therapy
KW - Bone Marrow
KW - Neoplasm Recurrence, Local/etiology
KW - Myeloproliferative Disorders/therapy
KW - Transplantation Conditioning
U2 - 10.1002/ajh.26833
DO - 10.1002/ajh.26833
M3 - SCORING: Journal article
C2 - 36606718
VL - 98
SP - 628
EP - 638
JO - AM J HEMATOL
JF - AM J HEMATOL
SN - 0361-8609
IS - 4
ER -